FDA Delays Subcutaneous Leqembi Starting Dose Decision

What Is Subcutaneous Leqembi and Why Does It Matter?

Lecanemab, marketed as Leqembi, is a monoclonal antibody approved by the FDA in 2023 for early Alzheimer's disease. It targets amyloid-beta plaques in the brain, which are believed to contribute to the progression of the disease. The current intravenous formulation requires patients to visit infusion centers every two weeks, a logistical burden that can limit access for many older adults with mobility or transportation challenges.

A subcutaneous version would allow patients or caregivers to administer the drug at home with a simple injection, similar to how insulin or certain biologic medications are given. Biogen and Eisai have been pursuing regulatory approval for both maintenance dosing and the critical initiation phase of treatment. The FDA's delay specifically affects the starting-dose application, which is essential for bringing new patients onto therapy without requiring infusion center visits.

How Does the FDA Delay Affect Alzheimer's Treatment Access?

For the estimated millions of Americans living with early Alzheimer's disease, access to disease-modifying treatments remains limited by infrastructure constraints. According to the Alzheimer's Association, infusion center capacity, geographic distribution, and insurance coverage have all created barriers since lecanemab's initial approval. A subcutaneous starting dose would have substantially lowered the barrier to entry for treatment.

The FDA delay does not necessarily indicate safety concerns; regulatory holdups often stem from manufacturing data review, additional information requests, or scheduling. Biogen and Eisai have stated they remain committed to working with the FDA to bring the subcutaneous formulation to patients. Analysts following the Alzheimer's drug pipeline note that subcutaneous administration is widely seen as critical to expanding lecanemab's commercial reach and clinical impact.

What Should Patients and Caregivers Know Right Now?

Patients who are already receiving intravenous Leqembi infusions are not affected by this regulatory delay and should continue treatment as directed by their neurologist. The drug's labeling, monitoring requirements (including regular MRI scans for ARIA — amyloid-related imaging abnormalities), and clinical recommendations remain unchanged.

For families exploring treatment options for a recently diagnosed loved one, the delay means subcutaneous initiation is not yet available. Discussions with neurologists about whether IV lecanemab is appropriate — including evaluation for amyloid-positive early Alzheimer's via PET imaging or cerebrospinal fluid testing — should not be postponed in anticipation of the subcutaneous formulation. Disease progression in early Alzheimer's is time-sensitive, and earlier treatment initiation is associated with greater clinical benefit in trial data.